nuRise - the only dosimeter capable to perform in-vivo and real time dose measurement at HDR and LDR regimes

1. Luís Moutinho | moutinho@ua.ptdose it well

2. CANCERthe global Killer
1 in 3 people
will develop cancer
during their lifetimes
is the leading cause of death in the developed world
and 8 million deaths
worldwide (2012)
14M new cases Prostate cancer
4th cancer
with highest incidence
1/3 are
prostate cancers
75%
by 2030
is the leading cause of death in the developed world
1. The problem

3. 1. The problem
surgery
chemotherapy
targeted therapy (hormone therapy, immunotherapy, gene therapy)
RT is one of the most efficient treatments,
however there’s
no quality assurance
in some modalities
radiotherapy (RT)

4. Dr. José Pérez Calatayud
Head of Radiophysics in Radiotherapy Unit of Hospital La Fe de Valencia
1. The problem
there’s a need for in-vivo real-time
dosimetry and real-time dose correction

5. 2. radiation detection
they are too bulky, not flexible and not sensitive enough
current solutions are not suitable for real-time in-vivo/in-situ dosimetry
real-time
low-energy
small size
in-vivo/in-situ
diodes diamondionization
chambers
MOSFET TLD
inorganic organic
scintillators

6. 3. Our product
Brachytherapy
needle
internal ø 1,067 mm
external ø 1,473 mm
17G x 20 cm
dose it well
dose probe 1 :025 µGy
dose probe 2: 020 µGy
dose probe 3: acquiring
dose334µGy
dosimeter for LDR and HDR brachytherapy
disposable probe
allows insertion through standard brachyterapy needles
main unit
(independent readout or
with PC for dose correction)
- integration with planning
software for real time dose
correction
- real time dose monitoring
in sensitive organs

7. 4. Our technology / uniqueness
Micropos Medical
Raypilot
Exradin
W1 scintillator
Best Medical Canada
Mosfet dosimeter
DRIM dose
(not in market)
Real-time
dose correction
LDR
brachytherapy
HDR
brachytherapy
?
the only dosimeter capable to perform in-vivo and real time
dose measurement at HDR and LDR regimes

8. 5. Global market and segmentation
is the leading cause of death in the developed worldprostate brachytherapy market
Dirac database
EuropeLatin America
Northern America
3388
645 1286
> 500 k patitents ongoing brachtytherapy
without proper quality assurance!
7620 radiotherapy
centers in the World:
SAM
>300 M€
# of treatments per radiotherapy center: (average)
LDR: 60/year HDR: 100/year
!!!

9. 6. Strategy / business model
key partners
key players

10. 201524 - 28 April
Barcelona, Spain
7. were we are
Business Idea Competition - prize Coimbra Inovação Parque | 1k€
1st place - Medical Devices & Health IT | 100k€
2012
Patent PT 1063372013
2014
2015
LDR and HDR in-vitro trials
Interaction with key players
in the brachythreapy field

11. €
in-vivo tests:
international IP:
final prototype:
40 k€ (Portugal only)
55 k€ (markets of interest)
~150 k€
8. where we're headed / fundraising
€
in-vitro trials
LDR/HDR
in-vivo trials
LDR/HDR
Product certification
fundraising
series seed

12. 9. revenue model
payback in the
2 year of salesnd
year
of sales
dosimeter
disposable probes LDR
disposable probes HDR
software
Time-to-market 3 to 4 years
Revenue forecast
€
Selling price
estimated
8000 €
115 €
185 €
-

13. JOÃO VELOSO
PhD in Tech. Physics
Head of DRIM research group
I3N, University of Aveiro
LUÍS MOUTINHO
M.Sc Biomedical devices
PhD student (Physics)
I3N, University of Aveiro
FILIPE CASTRO
Post-Doc
PhD in Physic Eng.
I3N, University of Aveiro
10. the team

14. CEO
dose it well
Luís Moutinho - moutinho@ua.pt
João Veloso - joao.veloso@ua.pt
Filipe Castro - ifcastro@ua.pt